SEC Form 4 · accession 0000921895-17-002745
Enveric Biosciences, Inc. · ENVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Giri Devanur
Officer — President & CEO
Period of report
Nov 17, 2017
Accepted (ET)
Nov 21, 2017 · 4:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000890821
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 17, 2017 | P | 12,121 | $4.115 | A | 2,191,346 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (Right to Buy)F1 | $4.115 | Nov 17, 2017 | P | 12,121 | A | Nov 17, 2017 | Nov 21, 2022 | Common Stock | 12,121 | 12,121 | D |
Explanation of responses
- F1The warrant gives the Reporting Person the right to purchase up to 12,121 shares of common stock at an exercise price equal to $4.115 per share. The warrant will expire on November 21, 2022.